J&J’s one-shot COVID vaccine offers hope for faster protection
On 29 January, Johnson and Johnson (J&J) announced that its vaccine was 66% effective overall in protecting against moderate to severe COVID-19, 28 days after trial participants received a single shot. Could this be the first one-shot vaccine to be approved?
Nature
Vaccine makers in Asia rush to test jabs against fast-spreading COVID variant
Vaccine makers in India and China are investigating whether their recently approved COVID-19 vaccines are effective against a fast-spreading variant of SARS-CoV-2, following similar investigations by the makers of other leading vaccines.
Nature
How COVID unlocked the power of RNA vaccines
The era of RNA vaccines has arrived—and dozens of companies are getting in the game. But future applications of the technology will run up against some challenges.
Nature
How to redesign COVID vaccines so they protect against variants
Scientists are exploring the idea of redesigning the vaccines currently being rolled out worldwide.
Nature
A pledge to immunize the world’s poorest people and end the pandemic
In June 2020 international funders undertook to buy enough COVID vaccines to immunize the 20% of people most vulnerable to the virus worldwide. But the project, a pioneering effort called COVAX, is struggling to meet expectations.
Nature
COVID vaccine rollout: fairness against speed
Busy phone lines, long queues and crashing websites are hampering attempts by many of the most vulnerable people in the US to get vaccinated, highlighting racial and economic inequalities.
Scientific American
Refreshing the biologic pipeline 2020
In the absence of face-to-face meetings, both the FDA and industry implemented regulatory workarounds to maintain drug and biologics approvals. These could be here to stay.
Nature Biotechnology
Top product forecasts for 2021
Lisa Urquhart, editor of Evaluate Vantage, a pharma and biotech news service, looks at the products that are forecast to have big sales in 2021.
Nature Reviews Drug Discovery
Oncology research needs a better map
It is time to move beyond tumor sequencing data to identify vulnerabilities in cancers, say the authors of the Comment article.
Nature
The breast cancer drug market
The latest piece in this From The Analyst’s Couch series explores the current therapies available to treat breast cancer and the new therapies that are emerging.
Nature Reviews Drug Discovery
Detecting Alzheimer’s with a simple blood test
New assays could reduce the need for costlier, more invasive brain scans and spinal fluid measures.
Scientific American
